In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), with a price target of $10.00. The company’s shares closed last Monday at $2.58, close to its 52-week low of $2.43.
According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of -18.5% and a 29.2% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Hookipa Pharma, and PolyPid.
Arbutus Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.
Arbutus Biopharma’s market cap is currently $362.5M and has a P/E ratio of -2.93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
Read More on ABUS: